Cardiovascular BioTherapeutics, Inc. Announces Positive Pre-Clinical Results for Protein-Based Drug Candidate to Treat Osteoporosis

LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that it has successfully completed work on a new medical indication for its protein drug candidate, human fibroblast growth factor (FGF-1), in an animal model of bone growth. In this research project, conducted in collaboration with Michael Rosenblatt, M.D., of Tufts University Medical School, the effect of FGF-1 to stimulate new bone formation was examined and compared to human parathyroid hormone, a known stimulator of bone formation in humans. As shown in the Figure below, FGF-1 was almost 20-fold more potent, on a weight basis, than parathyroid hormone (PTH) in stimulating bone formation in mice

MORE ON THIS TOPIC